Skip to content
DataLookout
Menu

NCT07881601

Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol

StatusEnrolling by Invitation
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Enrolling by invitation only
    • Start date pushed from Oct 17, 2026 to Nov 4, 2026
    • Primary completion date: Dec 19, 2026 to Jan 8, 2027
    • Site contact updated
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Flow-Mediated Dilation (FMD)
Timeframe: Baseline, Week 4, Week 8

Secondary (9)

Change in Total Plasma CoQ10 Concentration
Change in Plasma Ubiquinol Concentration
Change in Plasma Ubiquinone Concentration
Change in Ratio of Reduced to Total CoQ10
Change in Plasma Nitric Oxide (NO)
Show 4 moreShow less
Change in LDL Oxidation Susceptibility
Change in Malondialdehyde (MDA) Levels
Change in Oxidized LDL (oxLDL) Levels
Change in Total Antioxidant Capacity (TAC)

Arms and interventions

Ubiquinol 200 mg/dayExperimental

Participants will receive Ubiquinol 200 mg/day, administered orally as two soft capsules once daily for 8 weeks. Participants will be instructed to take the capsules with water or warm water after breakfast or lunch containing fat.

Ubiquinone 200 mg/dayExperimental

Participants will receive Ubiquinone 200 mg/day, administered orally as two soft capsules once daily for 8 weeks. Participants will be instructed to take the capsules with water or warm water after breakfast or lunch containing fat.

PlaceboPlacebo comparator

Participants will receive identical placebo soft capsules orally as two capsules once daily for 8 weeks, according to the study randomization schedule.

Dietary supplements: Ubiquinol, Ubiquinone

Other: Placebo

Sites

1 site in 1 country

  • San Francisco Research InstituteSan Francisco, California, United States